Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Greenville, North Carolina Clinical Trials

A listing of Greenville, North Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (12) clinical trials

Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas

PRIMARY OBJECTIVES: I. To determine the activity of a smoothened, frizzled class receptor (SMO) and PTCH1 inhibitor in patients with meningiomas harboring SMO mutations as measured by 6-month progression free survival (PFS) and response rate. II. To determine the activity of a FAK inhibitor in patients with meningiomas harboring neurofibromin ...

Phase

2.51 miles

Learn More »

Determination of Efficacy Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

This is a Phase 2, double-blind, placebo-controlled, 2-arm, multi-center trial in which subjects will be randomized in a 1:1 ratio to receive either placebo or AG013. AG013 is a mouth rinse formulation of Lactococcus lactis strain sAGX0085, deficient in the gene coding for thymidylate synthase and producing human TFF1 (Trefoil ...

Phase

2.67 miles

Learn More »

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

GT-201 is a randomized, double-blind, placebo-controlled, multi-center study conducted in the U.S. to evaluate GC4419 administered IV for the reduction of incidence, duration, and severity of radiation induced oral mucositis in patients receiving cisplatin plus intensity-modulated radiation therapy for post-operative, or definitive treatment of locally advanced, non-metastatic squamous cell carcinoma ...

Phase

2.69 miles

Learn More »

A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)

The purpose of this study is to evaluate whether fostamatinib is safe and effective in treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).

Phase

2.69 miles

Learn More »

Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

A randomized, international, multi-center, double-blinded study in patients with pretreated unresectable locally advanced or metastatic HER2+ breast cancer who have had prior treatment with a taxane, trastuzumab, pertuzumab and T-DM1. Patients will be randomized in a 2:1 ratio to receive tucatinib or placebo in combination with capecitabine and trastuzumab. Stratification ...

Phase

2.69 miles

Learn More »

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Approximately 120 subjects will be randomized to receive either enteric-coated LYC-30937-EC 25 mg PO QD or matching placebo PO QD for the duration of 8 weeks. Randomization will be stratified based on previous exposure to anti-TNF agents such that at least 50% of the randomized subjects will be anti-TNF naïve ...

Phase

2.69 miles

Learn More »

Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Subjects who complete the 8 week treatment period of the double-blind, placebo-controlled study LYC-30937-2001 will have the option of receiving LYC-30397-EC 25 mg PO QD in this open-label extension study (LYC-30937-2002). Subjects meeting eligibility criteria will enter this open-label extension trial upon completion of the LYC-30937-2001 Week 8 study procedures. ...

Phase

2.69 miles

Learn More »

A Study to Evaluate the Safety Tolerability & Efficacy of MSDC 0602K in Patients With NASH

This is a randomized, double-blinded study of three doses of MSDC-0602K or placebo given orally once daily to subjects with biopsy proven NASH with fibrosis and no cirrhosis. Visits to the clinic will be at baseline, 1, 2, 3, 6, 9, and 12 months, with one 2- week follow-up visit. ...

Phase

2.69 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

This study comprises three sub-studies. The objective of sub-study 1 is to characterize the dose-response, efficacy, and safety of ABT-494 compared to placebo in inducing clinical remission in order to identify the induction dose of ABT-494 for further evaluation in sub-study 2. The objective of sub-study 2 is to evaluate ...

Phase

2.69 miles

Learn More »

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease

The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.

Phase

2.69 miles

Learn More »